ChemotherapyFDA-approvedFirst-line
Cytarabine
How it works
Interferes with DNA replication, preventing cancer cells from growing and dividing.
Cancer types
Leukemia— All patients
Efficacy
In clinical trials, around 70% of patients achieved complete remission with cytarabine-based therapy.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing L-Annamycin for Treating Refractory/Relapsed AML | Leukemia | phase-2 | — | Source → |
| Testing Different Doses of Cytarabine for Acute Myeloid Leukemia | Leukemia | phase-3 | — | Source → |
| Testing New Treatments for Young Adults with Intermediate Risk Acute Myeloid Leukemia | Leukemia | phase-2 | — | Source → |
| New Cancer Treatment Combination Shows Promise Against Leukemia | Leukemia | lab-study | The triple CAV combination exerted a far stronger inhibitory effect than any single agent or dual-drug combination (p < 0.01) and showed synergistic interactions (combination index <1). | Source → |
| Exosomes may help leukemia cells resist chemotherapy | Leukemia | lab-study | — | Source → |
| Combining Chidamide and Cytarabine May Help Treat Acute Myeloid Leukemia | Leukemia | lab-study | — | Source → |
| Combining Chemotherapy May Improve Leukemia Outcomes | Leukemia | phase-3 | IDAC-plus significantly improved relapse-free survival (RFS) compared to IDAC monotherapy (HR 0.62, p=0.019). | Source → |
| Combining Metformin, Chloroquine, and Cytarabine May Improve Leukemia Treatment | Leukemia | lab-study | — | Source → |
| Iron Overload May Contribute to Leukemia Resistance to Chemotherapy | Leukemia | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.